Meeting Preview | The ‘2026 Global Synthetic Biology Industry Development Blue Book’ will be released at the Frost & Sullivan Life Science New Investment Summit Forum Health Technology Session

The 20th Frost & Sullivan Global Growth, Innovation and Leadership Summit and 5th New Investment Conference, also known as the “2026 Frost & Sullivan Summit” or “Conference”, hosted by Frost & Sullivan, a world-leading growth consulting firm, will be held grandly in Shanghai from August 4-5, 2026. During the conference, a High-Level Forum on New Investments in Life Sciences will be launched. The forum includes three parallel sessions focusing on biomedicine, medical devices, and health technology, presenting cutting-edge topics and latest insights. With the core concept “Driving Change through Innovation, Staying Resilient and Achieving Long-Term Success”, the forum invites industry leaders, biomedicine and medical device companies, health technology firms, investment institutions, and professional service providers to discuss emerging trends in life sciences, innovative technologies, and global development paths, aiming to promote industrial advancement and global collaboration.

Currently, synthetic biology has evolved from laboratory research to a key battlefield in national strategic competition. The 2026 Government Work Report clearly states the need to foster emerging and future industries, making biomanufacturing a new economic growth point.This means that synthetic biology and biomanufacturing are no longer merely technical issues, but representNational security (supply chain autonomy), climate agenda (Dual Carbon/Zero Carbon) and economic growth (new quality productivity)the intersection of three major missions.

At this historic moment, Frost & Sullivan will release“2026 Global Synthetic Biology Industry Development Blue Book”on August 5, 2026, during the High-Level Forum on New Investments in Life Sciences · Health Technology Session in Shanghai, providing a top-level industry analysis report with international comparability value to global practitioners and helping industry development.

The Blue Book establishes a research framework that goes beyond a single regional perspective, covering global depth and the entire industrial chain. Through in-depth analysis of China, the United States, the European Union, the Middle East and key markets along the “Belt and Road” initiative, combined with systematic comparison of cross-border regulatory policies,using a comprehensive industrial chain map, country/region comparison and triple analysis lenses of regulation-technology-business,it effectively avoids common misconceptions in the industry and provides deep insights for corporate strategy makers and investment institutions with cross-regional comparison value and industrial reference significance.

Host City: Shanghai, China

Date: August 4-5, 2026

Conference Scale: 5,000+

Conference Format: Offline + Online Live Streaming

Organizer: Frost & Sullivan

Scan the QR code to register immediately

The Blue Book first clarifies the conceptual boundaries between synthetic biology and biomanufacturing, avoiding the trap of “everything can be synthetic biology”. Starting from the three narrative coordinates of “reading DNA → modifying DNA → writing/reprogramming life systems” in life science, it constructs a macro driving force model: Dual Carbon constraints × supply chain security × new quality productivity × upgrading health needs, demonstrating why synthetic biology becomes one of the most strategic industries globally today.

Source: Frost & Sullivan Analysis

Technological innovation is the core engine of synthetic biology development. The Blue Book analyzes in detail how CRISPR technology reshapes the genetic code, how the integration of AI and synthetic biology creates protein language models, how cell-free synthesis and modular construction create core factories, and how DBTL automation and standardization (DoE+high throughput+online sensing+digital twin) enable “replicable manufacturing” in biotechnology.

The Blue Book systematically outlines the complete chain of synthetic biology—upstream (tool layer), midstream (platform layer) and downstream (application layer)—and deeply analyzes its applications in seven fields: ①Biomedicine (production of intermediate materials, bacterial engineering, artificial viruses and phages, controlled cell and gene therapy); ②Food and Nutrition (alternative proteins, nutritional additives, flavorings); ③Agriculture (breeding, fertilizers); ④High-performance Materials (new polymer materials, high-performance proteins, living functional materials); ⑤Consumer Personal Care (multifunctional protein peptides, functional small molecules); ⑥Bulk Chemicals; ⑦Bioenergy. At the same time, it analyzes key companies in the upstream and downstream of the industrial chain.

Synthetic biology has become a key research area in major countries around the world. The Blue Book systematically compares the industrial ecosystems and regulatory frameworks of China, the United States, the European Union (including the UK), the Middle East and key countries along the “Belt and Road” initiative, providing policy guidance for global expansion.

Source: Frost & Sullivan Analysis

The Blue Book deeply analyzes the comparison of three business models: IP licensing (platform type), proprietary products (vertical type) and CDMO manufacturing (asset heavy), reviews the evolution of financing cycles—“capacity narrative” declining, “cash flow + product selection barriers” returning. Whether standardization, safety, compliance, performance purity consistency and global traceability can be achieved will become the core growth point of industry development. The Blue Book also provides forward-looking analysis of the challenges and future trends in synthetic biology.